Similar Posts
If Big Tech Bear Is Here, TQQQ Sliding To 2022 Lows Next?
PM Images Financial leverage is a great thing during economic booms and oversized stock market gains. That’s exactly the definition explaining the terrific returns outlined by the ProShares UltraPro QQQ ETF (NASDAQ:TQQQ) over the last decade. With a daily performance goal of 3x the gains of the NASDAQ 100 index, holding this security during a…
L&T Heavy Engineering Wins Significant Orders; Shares End 1.5% Higher
October 28, 2025October 28, 2025 Shares of Larsen & Toubro Ltd (L&T) ended 1.5% higher on 28th October after the company announced that its heavy engineering division has recently secured ‘significant’ orders in both international and domestic markets. L&T has classified the latest deals as ‘significant’, meaning they fall…
6 Best Stock Portfolio Trackers for Investors 2024 | Liberated Stock Trader
To build a balanced portfolio of stocks, you need a service that will help you track and report on your investments. ☆ Research You Can Trust ☆ My analysis, research, and testing stems from 25 years of trading experience and my Certification with the International Federation of Technical Analysts. As an investor for 20 years,…
CDA – Codan Limited
This is a solid business, I monitor them for a while but only bought them when they got rid of their satellite business as I think that will drag down the company, once that is out of the way and stock still trades cheap I load up. Their metal detector are world class and very…
VantagePoint Vantagepoint A.I. Hot Stocks Outlook for March 21, 2025 Stocks $SPY, $NKE, $FNV, $NOC, $AAPL, $META, $AMZN and $HD
Register for a Free Live Training Hot Stocks Outlook uses VantagePoint’s market forecasts that are up to 87.4% accurate, demonstrating how traders can improve their timing and direction. In this week’s video, VantagePoint Software reviews forecasts for SPDR SPY($SPY), Nike ($NKE), Franco-Nevada ($FNV), Northrop Grumman ($NOC), Apple ($AAPL), Meta Platforms ($META), Amazon ($AMZN) and Home Depot…
Novartis to acquire Avidity Biosciences for about $12 billion
Novartis to acquire Avidity Biosciences for about $12 billion Source link